November 2025 Investor Presentation Fiscal 2025 Fourth Quarter and Year End Financial Results Forward-Looking Statements and Non-GAAP Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. NJR cautions readers that the assumptions forming the basis for forward-looking statement ...

Financial Performance - Q4 FY2025 - GAAP gross revenue reached $3.2 billion, a year-over-year increase of 6.6%, while adjusted net revenue was $2.2 billion, up 5.8% year-over-year[10] - Adjusted EBITDA stood at $324 million, reflecting a 12% increase year-over-year, with an adjusted EBITDA margin of 14.4% on adjusted net revenue[10, 14] - Adjusted EPS increased by 27.7% year-over-year to $1.75[10, 14] Financial Performance - FY2025 - GAAP gross revenue was $12.0 billion, up 4.6% year-over-year, and adjusted net revenue was $8.7 billion, up 5.3% year-over-year[10, 17] - Adjusted EBITDA reached $1.2 billion, a 13.9% increase year-over-year, resulting in an adjusted EBITDA margin of 13.9% on adjusted net revenue[10, 17] - Adjusted EPS increased by 15.9% year-over-year to $6.12[10, 17] Backlog and Book-to-Bill Ratio - The company reported a Q4 book-to-bill ratio of 1.1x and a trailing twelve-month (TTM) book-to-bill ratio of 1.1x[10] - Backlog increased from $21.8 billion in 2024 to $23.1 billion in 2025[14, 17] Segment Performance - I&AF End Market (Q4 FY2025) - Critical Infrastructure saw gross revenue of $1.2 billion and adjusted net revenue of $989 million, with year-over-year growth of 5.9% and 9.2% respectively[20] - Water & Environmental had gross revenue of $807 million and adjusted net revenue of $583 million, experiencing a decrease of 4% and 1.1% respectively[20] - Life Sciences & Advanced Manufacturing reported gross revenue of $831 million and adjusted net revenue of $352 million, with year-over-year growth of 19% and 5.3% respectively[20] FY2026 Outlook - The company projects adjusted net revenue growth of 6% to 10% year-over-year[26] - Adjusted EPS is expected to be in the range of $6.90 to $7.30[26] - Free cash flow margin is projected to be between 7% and 8%[26]

Financial Performance & Growth Strategy - TE Connectivity's FY25 sales are projected to be over $17 billion, serving a connectivity market of approximately $130 billion[14] - The company aims for 6-8% growth through the cycle, driven by secular trends and both organic and inorganic opportunities[13, 30] - TE Connectivity targets 30%+ incremental operating margins and double-digit adjusted EPS growth[13, 30] - The company expects 100%+ free cash flow conversion of adjusted net income, with a disciplined capital strategy[13, 30] - Adjusted operating margin is expected to be approximately 21% in FY25[14, 34, 67] Segment Performance & Market Opportunities - Industrial Solutions is expected to generate approximately $8 billion in sales[15] - Transportation Solutions is expected to generate approximately $9 billion in sales[16] - The company anticipates over $4 billion in incremental revenue opportunity over the next 5 years from portfolio investments[25] - Transportation Solutions is targeting 4-6% growth over market through 2030, fueled by megatrends[70, 77] Strategic Initiatives - The company is focused on co-creating next-generation architectures with customers to drive value creation[13, 19] - Portfolio investments in areas like AI, next-generation energy, factory automation, and e-mobility are expected to drive strong content growth[25]

Investor Day November 20, 2025 NPI:CA Forward Looking Statements This written presentation, together with the accompanying oral presentation, contains certain forward-looking statements concerning the business and operations of Northland Power Inc. ("Northland") that constitute forward-looking information within the meaning of Canadian securities laws. Such forward-looking statements are provided for the purpose of presenting information about management's current expectations and plans. Readers are caution ...

Financial Performance - Voyage Revenues for Q3 2025 were $38891 thousand, slightly up from $38613 thousand in Q2 2025 but slightly down from $39069 thousand in Q3 2024[14] - Operating Income for Q3 2025 was $18784 thousand, down from $19176 thousand in Q2 2025 and $19836 thousand in Q3 2024[14] - Net Income for Q3 2025 was $18655 thousand, up from $13709 thousand in Q2 2025 and $15054 thousand in Q3 2024[14] - Adjusted EBITDA for Q3 2025 was $27600 thousand, slightly down from $27687 thousand in Q2 2025 and $28901 thousand in Q3 2024[14] - The TCE rate for Q3 2025 was $67094, down from $67883 in Q2 2025 and $69261 in Q3 2024[14] - Cash breakeven per vessel per day for Q3 2025 was $47460, up from $41150 in Q3 2024[15] Capital Allocation and Debt - Declared a distribution to common unitholders for the third quarter of $0050 per common unit[13] - Since inception of common unit buy-back program repurchased 420236 common units at an average price of $371 per common unit as of November 20 2025[13] - The Partnership redeemed all of the issued and outstanding Series B Preferred Units on July 25 2025[13] - Debt Outstanding is $2898 million on four LNG carriers, with two vessels debt-free[31] - Total estimated contract backlog is $085 billion[32]

Financial Performance - Total revenues for the first nine months of 2025 reached €127.0 million, an 8.9% increase compared to the same period in 2024, despite headwinds and reduced third-party sales [11] - Product sales amounted to €119.4 million, a 6.2% increase from €112.5 million in the first nine months of 2024 [51] - IXCHIQ® sales saw significant growth, reaching €7.6 million, a 330% increase compared to €1.8 million in the same period of 2024 [51] - The company experienced a significant reduction in operating cash burn, with €28.4 million compared to €76.7 million in the first nine months of 2024 [11] - Valneva anticipates product sales between €155 million and €170 million for 2025 [59] Product & Pipeline Updates - IXIARO®/JESPECT® sales increased by 12.5%, reaching €74.3 million compared to €66.0 million in the first nine months of 2024 [51] - DUKORAL® sales decreased slightly by 3.4%, with sales of €21.5 million compared to €22.3 million in the first nine months of 2024 [51] - Valneva completed all vaccinations in the VALOR Phase 3 study for VLA15 (Lyme disease vaccine) and expects efficacy read-out in H1 2026 [16, 27] - The global market for Shigella vaccine is expected to exceed $500 million annually [48] Strategic Initiatives - Valneva successfully refinanced its debt, enhancing financial flexibility to Q4 2030 [11] - The company secured a new $32.8 million IXIARO® contract with the U.S Department of Defense [16] - Valneva responded to the French government's call for IXCHIQ® to combat chikungunya outbreaks in La Réunion and Mayotte [16]

2025 Investor Day 1 Safety Instructions All figures are in Canadian dollars unless otherwise stated. David Galison Vice President, Investor Relations 3 3 Cautionary Statement This presentation contains statements that are forward-looking in nature. The words "may", "could", "should", "would", "assumptions", "plan", "strategy", "believe", "anticipate", "estimate", "expect", "intend", "objective", the use of the future and conditional tenses, and words and expressions of similar nature are intended to identif ...

Financial Outlook and Strategy - Moderna anticipates up to 10% revenue growth in 2026, driven by new products and geographic expansion[2,138] - The company aims to improve gross margin by 10 percentage points over the next three years through volume increases, productivity improvements, and waste reduction[2,88] - Moderna is targeting cash breakeven in 2028, supported by a strong balance sheet and a $1.5 billion credit facility[2,131,138] - Projected cash costs are expected to reduce to $3.5-3.9 billion in 2027[138] Vaccine Portfolio - Seasonal vaccines are expected to be the backbone of Moderna's revenue growth over the next three years[27] - The company plans to expand its seasonal vaccine franchise to up to six approved products by 2028[2] - Moderna expects to enter the global flu vaccine market in the 2027/28 season with mRNA-1010, with regulatory filings expected by January 2026[67] - The company has submitted mRNA-1083 (Flu + COVID combo) for approval to Health Canada and is under review with the EMA[69] Oncology and Rare Disease Therapeutics - Moderna is investing cash generated from vaccines into oncology and rare disease therapeutics[10,34] - Investments in late-stage oncology and rare disease programs are expected to drive additional growth in 2027-2028[37,74] - The company is executing registrational studies in rare diseases and investing in early-stage autoimmune therapeutics[128]

Company Overview - APEI provides post-secondary education to over 108,000 students annually [18] - The company's 2024 revenue was $624.6 million and adjusted EBITDA was $72.3 million [20] - As of September 30, 2025, APEI had $193.1 million in cash and $96.4 million in debt [20] APUS Global (American Public University System) - APUS is the 1 educator of active-duty military and veterans [28] - Approximately 72% of APUS students graduate without APUS-incurred federal student loan debt [34, 81] - APUS and University of Maryland Global Campus together hold 47% of the total market share among ~2,350 Tuition Assistance (TA)-eligible institutions [91] - APUS aims to grow revenue from a midpoint of $314 million in 2025 guidance to $405 million - $420 million by 2029 through organic growth [164] - APUS projects adjusted EBITDA to grow from a midpoint of $92 million in 2025 guidance to $125 million - $130 million by 2029 [167] RU Health+ (Rasmussen University and Hondros College of Nursing) - RU Health+ operates 26 campuses in eight states [28, 194] - RU Health+ has ~13,600 students in nursing, allied health, and other health sciences programs [216] - RU Health+ projects revenue to grow from a midpoint of $320 million in 2025 guidance to $485 million - $505 million by 2029 [300] - RU Health+ projects adjusted EBITDA to grow from a midpoint of $14 million in 2025 guidance to $85 million - $100 million by 2029 [302] Financial Outlook - APEI targets revenue growth to ~$1.0 billion and adjusted EBITDA to $190 million - $200 million by 2029 [340]

Financial Performance (Q3 2025) - Time charter revenues were $51.9 million, compared to $57.5 million in Q3 2024[33, 34] - Net income was $7.2 million, an increase from $3.7 million in Q3 2024[33, 34] - Earnings per common share, diluted, were $0.05, compared to $0.00 in Q3 2024[33] - Adjusted EBITDA was $20.3 million, compared to $23.7 million in Q3 2024[33, 75] Financial Position (as of September 30, 2025) - Cash, cash equivalents, time deposits, and restricted cash totaled $133.9 million, a decrease from $207.2 million as of December 31, 2024[21, 33] - Long-term debt and finance liabilities, net of deferred financing costs, were $651.1 million, an increase from $637.5 million as of December 31, 2024[33] - Net debt to market value was 54%[21] Fleet and Chartering - The company had 36 vessels on the water[21, 34] - Average fleet utilization was 99.5% for the nine months ended September 30, 2025[21, 37] - Secured revenues of $25.4 million for 87% of the remaining ownership days of 2025 and $118.3 million for 50% of the ownership days of 2026[26, 32] - Average daily TC rate of fixed revenues is $16,223 for the remaining of 2025[32] Other Key Points - The company acquired 14.93% of Genco Shipping & Trading Ltd issued and outstanding common shares as of September 29, 2025[26] - Declared a cash dividend of $0.01 per common share for Q3 2025[26] - The dry bulk orderbook as % of total fleet is 10.9%[61]